Morepen Laboratories has successfully completed the first phase of its manufacturing capacity expansion program ahead of the previously indicated timeline. Under this first phase, the company’s installed reactor capacity for API and CDMO has increased from 535 KL to 614 KL.
This capacity enhancement strengthens the company’s manufacturing readiness for the ongoing scale-up of commercial CDMO supplies, while also supporting its existing API business and future customer programs.
The capacity expansion plays a key role in the company’s strategy to build a larger, scalable and globally compliant manufacturing platform, focused on long-duration customer partnerships and sustained growth across its API and CDMO businesses.
Morepen Laboratories is engaged in the manufacturing and sale of APis/ Bulk Drugs, Home Diagnostics, Formulations and OTC products.
